0001564590-20-012503.txt : 20200324 0001564590-20-012503.hdr.sgml : 20200324 20200324160602 ACCESSION NUMBER: 0001564590-20-012503 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200324 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200324 DATE AS OF CHANGE: 20200324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allakos Inc. CENTRAL INDEX KEY: 0001564824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454798831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38582 FILM NUMBER: 20738427 BUSINESS ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-597-5002 MAIL ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 8-K 1 allk-8k_20200324.htm 8-K allk-8k_20200324.htm
false 0001564824 0001564824 2020-03-24 2020-03-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 24, 2020

 

Allakos Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

 

001-38582

 

45-4798831

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

975 Island Drive, Suite 201

Redwood City, California 94065

(Address of principal executive offices, including zip code)

(650) 597-5002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001

ALLK

The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

Item 8.01 Other Events

On March 24, 2020, Allakos Inc. (the “Company”) issued two press releases announcing the initiation of antolimab (AK002) clinical studies and positive Phase 1 results with antolimab (AK002) in mast cell gastrointestinal disease. The full text of the press releases issued in connection with these announcements are attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release dated March 24, 2020.

 

 

 

99.2

 

Press Release dated March 24, 2020.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Allakos Inc.

 

 

 

 

Date: March 24, 2020

 

By:

/s/ Robert Alexander

 

 

 

Robert Alexander

 

 

 

Chief Executive Officer

 

2

 EX-99.1 2 allk-ex991_6.htm EX-99.1 allk-ex991_6.htm

Exhibit 99.1

 

Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies

 

 

•

Phase 3 study of antolimab for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis)

 

•

Phase 2/3 study of antolimab for the treatment of eosinophilic esophagitis

 

•

Phase 1 study of subcutaneously administered antolimab in healthy volunteers

 

-- Management to host conference call and webcast today at 5:00 pm ET --

 

REDWOOD CITY, Calif., March 24, 2020 – Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), a Phase 2/3 study in eosinophilic esophagitis (EoE), and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers. The Phase 3 EG and/or EoD study and the Phase 2/3 EoE study follow positive results from ENIGMA, the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 2 study in patients with EG and/or EoD.

 

Phase 3 Eosinophilic Gastritis (EG) and/or Eosinophilic Duodenitis (EoD) Study Design

The multicenter, randomized, double-blind, placebo-controlled Phase 3 trial will enroll approximately 160 patients with active, biopsy-confirmed EG (eosinophil count of ≥30 eosinophils in 5 high powered fields [hpfs] in the stomach) and/or EoD (eosinophil count of ≥30 eosinophils in 3 hpfs in duodenum). Patients will be randomized 1:1 to receive: (a) 1.0 mg/kg of antolimab for the first month followed by five doses of 3.0 mg/kg given monthly, or (b) monthly placebo. The co-primary endpoints of the study are: 1) the proportion of patients achieving ≤ 4 eosinophils in 5hpfs in the stomach and/or ≤15 eosinophils in 3hpfs in the duodenum and 2) absolute change in Total Symptom Score (TSS-6: abdominal pain, nausea, bloating, early satiety, abdominal cramping, loss of appetite) measured using the daily patient reported symptom questionnaire used in ENIGMA. The TSS-6 consists of the six most frequent and severe symptoms reported in ENIGMA.

 

Phase 2/3 Eosinophilic Esophagitis (EoE) Study Design

The multicenter, randomized, double-blind, placebo-controlled Phase 2/3 trial will enroll approximately 300 patients with active, biopsy-confirmed EoE (eosinophil count of ≥15 eosinophils in a single hpf). Patients will be randomized 1:1:1 to receive: (a) six antolimab doses of 1.0 mg/kg given monthly, (b) 1.0 mg/kg of antolimab for the first month followed by five doses of 3.0 mg/kg given monthly, or (c) monthly placebo. The co-primary endpoints of the study are: (1) the proportion of patients achieving ≤6 eosinophils in a single hpf and (2) absolute change in dysphagia symptoms measured using a daily patient reported symptom questionnaire known as the Dysphagia Symptom Questionnaire (DSQ).

 

Phase 1 Study of Subcutaneously Administered Antolimab in Healthy Volunteers

The randomized, double-blind, placebo-controlled Phase 1 trial will evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneously administered antolimab in healthy volunteers.

 

Conference Call and Live Webcast
The Company will host a conference call and webcast with slides today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial 877-407-9039 (domestic) or 201-689-8470 (international). The conference ID number is 13700828. A live and archived audio webcast can be accessed

 

through the Investors section of the Company's website at www.allakos.com. The archived audio webcast will remain available on the Company's website for 30 days following the conference call.

 

About Eosinophilic Gastritis, Eosinophilic Duodenitis, and Eosinophilic Esophagitis

Eosinophilic gastritis, eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), and eosinophilic esophagitis are severe inflammatory orphan diseases characterized by the presence of high levels of eosinophils in the stomach, duodenum, or esophagus, respectively. Common symptoms of the diseases include severe abdominal pain, nausea, diarrhea, bloating, cramping, early satiety, loss of appetite, vomiting, dysphagia, and weight loss. The current estimated prevalence of eosinophilic gastritis and eosinophilic duodenitis in the United States is approximately 50,000 people. The estimated prevalence of eosinophilic esophagitis in the United States is approximately 150,000 people. There are no treatments approved specifically for these diseases. Treatment with systemic steroids can provide symptomatic improvement, but long-term treatment with steroids is generally not possible due to the numerous side effects. Allakos has received orphan drug designation for antolimab in eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic esophagitis.

About Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab has been tested in six clinical studies. In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize antolimab, its lead compound; Allakos’ ability to obtain required regulatory approvals and appropriate labelling for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond antolimab; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on February 25, 2020, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for

 

Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.

 

 

###

Source: Allakos Inc.

 

Investor Contact:

 

Media Contact:

Adam Tomasi, President and COO

 

Denise Powell

ir@allakos.com

 

denise@redhousecomms.com

 

 

 EX-99.2 3 allk-ex992_20.htm EX-99.2 allk-ex992_20.htm

Exhibit 99.2

 

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

 

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease --

 

-- Management to host conference call and webcast today at 5:00 pm ET --

 

REDWOOD CITY, Calif., March 24, 2020 – Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported results from a Phase 1 study evaluating the safety and efficacy of antolimab for the treatment of patients with mast cell gastrointestinal disease.

 

Mast Cell Gastrointestinal Disease

During enrollment of the Company’s Phase 2 ENIGMA study in patients with eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), patients were identified with chronic moderate to severe gastrointestinal symptoms and elevated stomach and/or duodenal mast cell counts who did not have elevated eosinophils counts. These patients appeared to have a mast cell driven condition, currently referred to as mast cell gastrointestinal disease (MGID), and were offered the opportunity to participate in an open-label study of antolimab.

 

Phase 1 MGID Study Design

This open-label, multi-dose, 6-month, Phase 1 trial of antolimab consisted of seven patients with moderate to severe gastrointestinal symptoms and elevated mast cells (≥30 mast cells per hpf in at least 5hpfs in the stomach and/or ≥30 mast cells per hpf in at least 3hpfs in the duodenum) who did not have elevated eosinophils. Patients received 0.3 mg/kg of antolimab for the first dose, followed by 1.0 mg/kg the following month, then monthly doses of 3.0 mg/kg for four additional months. Disease symptoms were assessed using a daily patient reported questionnaire measuring eight symptoms (Total Symptom Score [TSS-8: abdominal pain, nausea, vomiting, early satiety, loss of appetite, abdominal cramping, bloating, and diarrhea]).

 

Study Results

Six-month treatment with antolimab resulted in a 64 percent mean reduction in TSS-8 compared to baseline. Five of seven (71 percent) patients had >50 percent reduction in TSS-8. The treatment effect of antolimab in this open label study was similar to that observed with antolimab in patients with EG and/or EoD in the Phase 2 ENIGMA Study.

 

Tissue and Symptom Results

MGID (N=7)

Baseline

% Change

Change in median GI eosinophil counts

17 eos/hpf

-100%

Change in median GI mast cell counts

55 mc/hpf

-18%

Mean change in Total Symptom Score (TSS-8)

27.1

-64%

 

Safety
Antolimab was generally well tolerated and no drug-related serious adverse events occurred during the study. The most common treatment emergent adverse event was infusion related reactions, all of which were mild.

 

 

Given the encouraging treatment response observed in this study, MGID may represent a novel market opportunity. Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.

 

Conference Call and Live Webcast
The Company will host a conference call and webcast with slides today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial 877-407-9039 (domestic) or 201-689-8470 (international). The conference ID number is 13700828. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.allakos.com. The archived audio webcast will remain available on the Company's website for 30 days following the conference call.

About Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab has been tested in six clinical studies. In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, Allakos’ progress and business plans and plans relating to its future clinical trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize antolimab (AK002), its lead compound; Allakos’ ability to obtain required regulatory approvals and appropriate labelling for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond antolimab (AK002); Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on February 25, 2020, and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement,

 

except as required by law. These forward-looking statements should not be relied upon as representing Allakos’ views as of any date subsequent to the date of this press release.

 

 

###

Source: Allakos Inc.

 

Investor Contact:

 

Media Contact:

Adam Tomasi, President and COO

 

Denise Powell

ir@allakos.com

 

denise@redhousecomms.com

 

 GRAPHIC 4 grz1rahbboj0000001.jpg GRAPHIC begin 644 grz1rahbboj0000001.jpg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end GRAPHIC 5 ggrln12gxudm000001.jpg GRAPHIC begin 644 ggrln12gxudm000001.jpg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end EX-101.SCH 6 allk-20200324.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 7 allk-20200324_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of Each Class Security12b Title Trading Symbol Trading Symbol Name of Each Exchange on Which Registered Security Exchange Name EX-101.PRE 8 allk-20200324_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "allk-8k_20200324.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "allk-8k_20200324.htm" ] }, "labelLink": { "local": [ "allk-20200324_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "allk-20200324_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "allk-20200324.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "allk", "nsuri": "http://www.allakos.com/20200324", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "allk-8k_20200324.htm", "contextRef": "C_0001564824_20200324_20200324", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "allk-8k_20200324.htm", "contextRef": "C_0001564824_20200324_20200324", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "verboseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of Each Class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of Each Exchange on Which Registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 10 0001564590-20-012503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-012503-xbrl.zip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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document And Entity Information
Mar. 24, 2020
Cover [Abstract]  
Entity Registrant Name Allakos Inc.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001564824
Document Period End Date Mar. 24, 2020
Entity Emerging Growth Company false
Entity File Number 001-38582
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4798831
Entity Address, Address Line One 975 Island Drive
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 597-5002
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of Each Class Common Stock, par value $0.001
Trading Symbol ALLK
Name of Each Exchange on Which Registered NASDAQ

XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allakos.com/20200324/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports allk-8k_20200324.htm allk-20200324.xsd allk-20200324_lab.xml allk-20200324_pre.xml allk-ex991_6.htm allk-ex992_20.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 allk-8k_20200324_htm.xml IDEA: XBRL DOCUMENT 0001564824 2020-03-24 2020-03-24 false 0001564824 8-K 2020-03-24 Allakos Inc. DE 001-38582 45-4798831 975 Island Drive Suite 201 Redwood City CA 94065 650 597-5002 Common Stock, par value $0.001 ALLK NASDAQ false false false false false